Navigation Links
Tengion Reports Fourth Quarter and Full Year 2011 Financial Results
Date:3/26/2012

WINSTON-SALEM, N.C., March 26, 2012/PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today reported its financial results for the year ended December 31, 2011 and provided a business and clinical update detailed in a separate press release issued today, in which the Company reported that it has made significant advances in its two lead programs.

"We have made significant progress advancing our Neo-Urinary Conduit and Neo-Kidney Augment programs and I believe we have created strong momentum to build upon as we continue to execute on our aggressive development goals in 2012," stated John L. Miclot, President and Chief Executive Officer of Tengion. "A fourth patient has now been enrolled and implanted in our Neo-Urinary Conduit clinical trial and we have submitted a pre-Investigational New Drug filing to FDA for our Neo-Kidney Augment one quarter ahead of schedule."

Financial UpdateFor the year ended December 31, 2011, the Company reported an adjusted net loss of $24.4 million, or $1.13 per basic and diluted common share, compared with an adjusted net loss of $25.8 million, or $2.80 per basic and diluted common share, for the same period in 2010.  

The decreased adjusted net loss for the 2011 period was primarily due to a decrease in interest expense of $1.2 million resulting from lower average debt balances outstanding in 2011, and a decrease in depreciation expense of $1.7 million resulting from both a change in the estimated useful life of leasehold improvements at the Company's leased facility in Winston-Salem, North Carolina and the impairment of the Company's leased facility in East Norriton, Pennsylvania.
These decreases were offset in part by increased general and administrative expense of $1.2 million related to restructuring charges incurred during 2011 and an increase in research and development expense of $0.4 m
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
(Date:9/2/2014)... , Sept. 2, 2014  Cyberonics, Inc. ... from the ANTHEM-HF clinical study.  Results of the ... during a major European cardiology congress and concurrently ... show Autonomic Regulation Therapy (ART) in patients ... impaired heart function is safe, improves the heart,s ...
(Date:9/2/2014)... , Sept. 2, 2014  Based on ... treatment device market, Frost & Sullivan recognizes Novian ... & Sullivan Award for Technology Innovation Leadership. Novian ... fibroadenoma and malignant tumors with its proprietary technology, ... is a reliable, accurate, and easy-to-control ultrasound-guided thermo ...
Breaking Medicine Technology:Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... , CINCINNATI , June 21 ... to its HARMONIC® line of surgical devices, the HARMONIC ... designed to extend the reach of surgeons for minimally ... (or 9cm) than the standard length HARMONIC ACE® device. ...
... today announced that six-month clinical follow-up data show the safety and ... (Sequent Please®, B.Braun) followed by implantation of the company,s Genous Bio-engineered ... , , ... single center, all-comers POTENT ( P aclitaxel-eluting ball O on and ...
Cached Medicine Technology:Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 2Data Show OrbusNeich's Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon 3
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... other new blood thinners is growing at a rapid ... continue to mount in courts around the U.S., Bernstein ... in American Journal of Medicine, within a year of ... be prescribed Xarelto as warfarin, a blood thinner that ...
(Date:9/2/2014)... 2014 (HealthDay News) -- Complications are rare among ... a new study indicates. However, the researchers ... with a slightly higher risk for certain complications ... more than 18,000 breast cancer patients who had ... with breast reconstruction and were followed for 30 ...
(Date:9/2/2014)... September 2, 2014 In a large population-based ... found that mild cognitive impairment (MCI) occurred twice ... type 2. Interestingly, this strong association was only ... older participants (66-80 years) the association vanished. This ... Alzheimer,s Disease . , The concept of MCI ...
(Date:9/2/2014)... Medex Analytic Services is delighted to ... Coral Springs, Fla. due to their greater than forecasted ... for the 2014 year by distinguishing Medex in the ... a higher level of service and professionalism in the ... the industry has responded.” , The location of the ...
(Date:9/2/2014)... Kathleen Doheny HealthDay Reporter ... obesity epidemic is a driving force behind the rising rates ... Researchers looked at data from five national surveys spanning from ... diabetes over time could be explained by factors such as ... The investigators found that the prevalence of diabetes in ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Medex Analytic Services Announces New Location for Corporate Headquarters 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3
... HBV is small in size. The genome of this virus ... stranded, this genome carries about 3000 base pairs, compared to ... virus. These 3000 base pairs encode an envelope protein, a ... very special X protein, named such because its function was ...
... a curriculum-based bullying prevention program reduced incidents of bullying by ... group. , Jeffrey M. Jenson and William A. Dieterich of ... more than 1,100 students in 28 elementary schools in Denver ... prevention program called Youth Matters (YM). A second control ...
... is the first to document a genetic mutation linked to ... it is likely to give them new insight into how ... Annex, professor of medicine and director of vascular medicine at ... Over and over, Id see two patients show up ...
... higher prevalence of stroke than their European counterparts, due in ... Americans and barriers to care in the United States, according ... Stroke Conference 2008. , Compared to European men, U.S. men ... U.S. women had almost twice the odds of stroke as ...
... of public town hall meetings to gather feedback from the public ... the role of genes and environment in health. The town halls ... Institutes of Health and other federal health agencies discussions as they ... , One way to study a host of common diseases - ...
... Finding may provide benefit for HIV, bone marrow transplantation ... possible to stimulate the thymus gland to produce new ... researchers say. , HIV infection destroys T-cells, which leads ... infection. The thymus gland produces T-cells early in life ...
Cached Medicine News:Health News:Who found some new mechanisms of HBV virulence? 2Health News:University of Denver bullying victimization study 2Health News:Genetic mutation found in peripheral artery disease 2Health News:Stroke more prevalent in United States than in Europe 2Health News:Stroke more prevalent in United States than in Europe 3Health News:Genetic town halls to be held in 5 US cities 2Health News:Stimulating Thymus Reactivates T-Cell Production 2
... system delivers on the promise of ... the latest advancement in fluidics control ... Lomb Surgical offers CONCENTRIX™ Fluidics Control ... provide both flow and vacuum response. ...
... excellent maneuverability. Konan made it ... high quality. Easy switchover from ... changing the adapter. Konan's development ... in a sharp image from ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... These plugs are coated with ... (PVP) that makes the surface ... drainage and to prevent debris ... For partial occlusion. For partial ...
Medicine Products: